Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill plus chemo aims to tackle tough lymphoma

NCT ID NCT07409428

Disease control Sponsor: Hutchmed Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This Phase 3 trial tests whether adding an experimental pill (HMPL-760) to standard chemotherapy (R-GemOx) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). About 240 adults will be randomly assigned to get either the new drug or a placebo, plus chemo. The main goal is to see if the combo delays cancer growth or improves survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HMPL-760 (a targeted cancer drug taken as a pill) plus R-GemOx (rituximab, gemcitabine, oxaliplatin chemotherapy)
What this could lead to
If successful, this could offer a new treatment option for people with aggressive lymphoma that has come back or not responded to prior therapy.
What could go wrong
This is an early Phase 3 trial, so results are not yet known. The drug may not improve outcomes and could cause side effects like those from chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Sign the ICF and be able to follow the requirements of study protocol; 2. Age ≥18 years; 3. ECOG performance status score between 0 and 2; 4. Histopathologically confirmed diagnosis of DLBCL; 5. The investigator judges that the patient's current condition requires further treatment; 6. Patients should have at least one bi-dimensionally measurable lesion; 7. Expected survival is more than 12 weeks; Exclusion Criteria: 1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL; 2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding; 3. Organ insufficiency; 4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV); 5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug; 6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin); 7. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria); 8. Clinically significant active infection;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsed/refractory diffuse large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsed/refractory diffuse large B-cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    50 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • BEIJING TONGREN HOSPITAL, Capital Medical University

    RECRUITING

    Beijing, China

  • Baoding NO.1 Central Hospital

    RECRUITING

    Baoding, China

  • Beijing GoBroad Hospital

    RECRUITING

    Beijing, China

  • Chongqing University Cancer Hospital

    RECRUITING

    Chongqing, China

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, China

  • Fujian Medical University Union Hospital

    RECRUITING

    Fuzhou, China

  • Guangdong Provincial People's Hospital

    NOT_YET_RECRUITING

    Guangzhou, China

  • Harbin Medical University Cancer Hospital

    RECRUITING

    Harbin, China

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, China

  • Hubei Cancer Hospital

    RECRUITING

    Wuhan, China

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, China

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

    RECRUITING

    Tianjin, China

  • Jiangsu Cancer Hospital

    RECRUITING

    Nanjing, China

  • Jiangxi Cancer Hospital

    RECRUITING

    Nanchang, China

  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School

    NOT_YET_RECRUITING

    Nanjing, China

  • North China University of Science and Technology Affiliated Hospital

    RECRUITING

    Tangshan, China

  • People's Hospital of Hunan Province

    RECRUITING

    Changsha, China

  • People's Hospital of Xinjiang Uygur Autonomous Region

    NOT_YET_RECRUITING

    Ürümqi, China

  • Qilu Hospital of Shandong University

    NOT_YET_RECRUITING

    Jinan, China

  • Quanzhou First Hospital.Fujian

    RECRUITING

    Fujian, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, China

  • Shandong Cancer Hospital & Institute

    RECRUITING

    Jinan, China

  • Shanxi Provincial Cancer Hospital

    RECRUITING

    Taiyuan, China

  • Shengjing Hospital of China Medical University

    NOT_YET_RECRUITING

    Shenyang, China

  • Shenzhen people's hospital

    NOT_YET_RECRUITING

    Shenzhen, China

  • Sichuan Provincial People's Hospital

    RECRUITING

    Chengdu, China

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, China

  • The Affiliated Hospital of Guizhou Medical University

    RECRUITING

    Guiyang, China

  • The Affiliated Hospital of Qingdao University

    RECRUITING

    Qingdao, China

  • The Affiliated Hospital of Xuzhou Medical University

    NOT_YET_RECRUITING

    Xuzhou, China

  • The First Affiliated Hospital of Bengbu Medical College

    RECRUITING

    Bengbu, China

  • The First Affiliated Hospital of Chongqing Medical University

    NOT_YET_RECRUITING

    Chongqing, China

  • The First Affiliated Hospital of Guangxi Medical University

    RECRUITING

    Nanning, China

  • The First Affiliated Hospital of Kunming Medical University

    NOT_YET_RECRUITING

    Kunming, China

  • The First Affiliated Hospital of WMU

    NOT_YET_RECRUITING

    Wenzhou, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    RECRUITING

    Xi'an, China

  • The First Affiliated Hospital of Xiamen University

    NOT_YET_RECRUITING

    Xiamen, China

  • The First Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, China

  • The First Affiliated Hospital, Zhejiang University

    NOT_YET_RECRUITING

    Hangzhou, China

    Contact Email: •••••@•••••

  • The First Hospital of Jilin University

    RECRUITING

    Changchun, China

  • The Second Affiliated Hospital of Anhui Medical University

    RECRUITING

    Hefei, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)

    NOT_YET_RECRUITING

    Xi'an, China

  • The Second Xiangya Hospital of Central South University

    RECRUITING

    Changsha, China

  • Tianjin Medical University Cancer Institute & Hospital

    RECRUITING

    Tianjin, China

  • Tianjin People's Hospital

    RECRUITING

    Tianjin, China

  • Tongji Hospital of Tongji University

    RECRUITING

    Shanghai, China

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, China

  • Wuhan Union Hospital of China

    RECRUITING

    Wuhan, China

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, China

  • ZhuJiang Hospital of Southern Medical University（The Second Clinical Medical College）

    RECRUITING

    Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.